Literature DB >> 11449029

In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease.

T Murai1, U Müller, K Werheid, D Sorger, M Reuter, T Becker, D Y von Cramon, H Barthel.   

Abstract

Parkinson's disease affects various neurotransmitter systems. Using SPECT, the authors measured [(123)I]beta-CIT binding ratios of the caudate, putamen, medial thalamus, and dorsal midbrain over cerebellum in 16 patients with Parkinson's disease, and examined correlations with clinical ratings. Whereas striatal binding ratios (reflecting regional dopamine transporter densities) were associated with motor symptoms, dorsal midbrain binding ratios (reflecting regional serotonin transporter densities) were significantly correlated with the mentation, behavior, and mood subscale of the Unified Parkinson's Disease Rating Scale. These findings indicate that degeneration of the nigrostriatal dopaminergic neurons and a dysfunctional serotonergic raphe system contribute differentially to motor deficits and neuropsychiatric symptoms in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11449029     DOI: 10.1176/jnp.13.2.222

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  26 in total

1.  Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.

Authors:  Tonya N Taylor; Shawn P Alter; Minzheng Wang; David S Goldstein; Gary W Miller
Journal:  Neuropharmacology       Date:  2013-09-08       Impact factor: 5.250

2.  Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study.

Authors:  V Caretti; D Stoffers; A Winogrodzka; I-U Isaias; G Costantino; G Pezzoli; C Ferrarese; A Antonini; E-Ch Wolters; J Booij
Journal:  J Neural Transm (Vienna)       Date:  2008-03-12       Impact factor: 3.575

Review 3.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

4.  The Role of the Serotonergic System in REM Sleep Behavior Disorder.

Authors:  Dario Arnaldi; Francesco Famà; Fabrizio De Carli; Silvia Morbelli; Michela Ferrara; Agnese Picco; Jennifer Accardo; Alberto Primavera; Gianmario Sambuceti; Flavio Nobili
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

Review 5.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 6.  Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data.

Authors:  B Scholtissen; F R J Verhey; H W M Steinbusch; A F G Leentjens
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

7.  Is correction for age necessary in neuroimaging studies of the central serotonin transporter?

Authors:  Swen Hesse; Henryk Barthel; Toshiya Murai; Ulrich Müller; Dominic Müller; Anita Seese; Regine Kluge; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-16       Impact factor: 9.236

Review 8.  Parkinson's disease-related disorders in the impulsive-compulsive spectrum.

Authors:  Eric Ch Wolters; Ysbrand D van der Werf; Odile A van den Heuvel
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 9.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

10.  Monoamine transporter availability in Parkinson's disease patients with or without depression.

Authors:  Swen Hesse; Philipp M Meyer; Karl Strecker; Henryk Barthel; Florian Wegner; Christian Oehlwein; Ioannis Ugo Isaias; Johannes Schwarz; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-27       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.